Home / VEGF-C / Recombinant Human VEGF-C Protein

Recombinant Human VEGF-C Protein

Catalog #: 9199-VC
14 Citations Datasheet

Carrier Free

Catalog # Availability Size / Price Qty
9199-VC-025/CF

With Carrier

Catalog # Availability Size / Price Qty
9199-VC-025
Recombinant Human VEGF-C Protein Bioactivity
1 Image
Product Details
Citations (14)
FAQs
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VEGF-C Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in a cell proliferation assay using HMVEC human microvascular endothelial cells. Marconcini, L. et al. (1999) Proc. Natl. Acad. Sci. USA 96:9671. The ED50 for this effect is 1.5-9 ng/mL.
Source
Chinese Hamster Ovary cell line, CHO-derived human VEGF-C protein
Ala112-Arg227
Accession #
P49767
N-terminal Sequence
Analysis
Ala112
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
13 kDa
SDS-PAGE
14-22 kDa, reducing conditions

Product Datasheets

You must select a language.

x

9199-VC (with carrier)

Product Datasheet

You must select a language.

x

9199-VC/CF (carrier free)

Product Datasheet

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

9199-VC

Formulation Lyophilized from a 0.2 μm filtered solution in HCl with BSA as a carrier protein.
Reconstitution Reconstitute at 250 μg/mL in 4 mM HCl.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

9199-VC/CF

Formulation Lyophilized from a 0.2 μm filtered solution in HCl.
Reconstitution Reconstitute at 250 μg/mL in 4 mM HCl.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity Recombinant Human VEGF-C Protein Bioactivity View Larger

Recombinant Human VEGF-C (Catalog # 9199-VC) induces HMVEC human microvascular endothelial cell proliferation. The ED50 for this effect is 1.5-9 ng/mL. The ED50 for the three competitors is >30 ng/mL, which is at least more than 10-fold weaker.

Background: VEGF-C

Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a subfamily of the angiogenic VEGF angiogenic factors (1). VEGF-C is synthesized as a 58 kDa molecule that consists of a VEGF homolgy domain (VHD) flanked by N- and C-terminal propeptides. The proprotein undergoes covalent homodimerization and stepwise proteolytic processing to generate ligands with increasing affinity for VEGF R3/Flt-4 (2-4). Fully processed VEGF-C containing just the 21 kDa VHD can additionally bind and activate VEGF R2/KDR/Flk-1 (2, 4). Fully processed human VEGF-C shares 98% amino acid sequence identity with mouse and rat VEGF-C. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis (5-8). VEGF-C and VEGF R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, resulting in enhanced lymph flow and metastasis to regional lymph nodes (9-12). It also induces physiological and intratumoral neoangiogenesis and vessel sprouting through interactions with VEGF R2 (8, 13, 14).

References
  1. Chen, J.-C. et al. (2013) Int. J. Mol. Sci. 14:88.
  2. Joukov, V. et al. (1996) EMBO J. 15:290.
  3. Kukk, E. et al. (1996) Development 122:3829.
  4. Joukov, V. et al. (1997) EMBO J. 16:3898.
  5. Karkkainen, M. et al. (2004) Nat. Immunol. 5:74.
  6. Jeltsch, M. et al. (1997) Science 276:1423.
  7. Makinen, T. et al. (2001) Nat. Med. 7:199.
  8. Laakkonen, P. et al. (2007) Cancer Res. 67:593.
  9. Hoshida, T. et al. (2006) Cancer Res. 66:8065.
  10. Mandriota, S.J. et al. (2001) EMBO J. 20:672.
  11. Skobe, M. et al. (2001) Nat. Med. 7:192.
  12. Padera, T.P. et al. (2002) Science 296:1883.
  13. Tammela, T. et al. (2008) Nature 454:656.
  14. Cao, Y. et al. (1998) Proc. Natl. Acad. Sci. 95:14389.
Long Name
Vascular Endothelial Growth Factor C
Entrez Gene IDs
7424 (Human); 22341 (Mouse)
Alternate Names
Flt4 ligand; Flt4-L; vascular endothelial growth factor C; Vascular endothelial growth factor-related protein; VEGFC; VEGF-C; VRPFLT4 ligand DHM

Citations for Recombinant Human VEGF-C Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

14 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Quantitative proteomics reveals CLR interactome in primary human cells
    Authors: Manolis, D;Hasan, S;Maraveyas, A;O'Brien, DP;Kessler, BM;Kramer, H;Nikitenko, LL;
    The Journal of biological chemistry
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. An EPHB4-RASA1 signaling complex inhibits shear stress-induced Ras-MAPK activation in lymphatic endothelial cells to promote the development of lymphatic vessel valves
    Authors: Chen, D;Wiggins, D;Sevick, EM;Davis, MJ;King, PD;
    bioRxiv : the preprint server for biology
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. A 3D biomimetic model of lymphatics reveals cell-cell junction tightening and lymphedema via a cytokine-induced ROCK2/JAM-A complex
    Authors: Lee, E;Chan, SL;Lee, Y;Polacheck, WJ;Kwak, S;Wen, A;Nguyen, DT;Kutys, ML;Alimperti, S;Kolarzyk, AM;Kwak, TJ;Eyckmans, J;Bielenberg, DR;Chen, H;Chen, CS;
    Proceedings of the National Academy of Sciences of the United States of America
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Zmiz1 is a novel regulator of lymphatic endothelial cell gene expression and function
    Authors: K C, R;Patel, NR;Shenoy, A;Scallan, JP;Chiang, MY;Galazo, MJ;Meadows, SM;
    bioRxiv : the preprint server for biology
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  5. pYtags enable spatiotemporal measurements of receptor tyrosine kinase signaling in living cells
    Authors: Farahani, PE;Yang, X;Mesev, EV;Fomby, KA;Brumbaugh-Reed, EH;Bashor, CJ;Nelson, CM;Toettcher, JE;
    eLife
    Species: Mouse
    Sample Types: Transfected Whole Cells
    Applications: Bioassay
  6. Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance
    Authors: R Islam, J Mishra, NS Polavaram, S Bhattachar, Z Hong, S Bodas, S Sharma, A Bouska, T Gilbreath, AM Said, LM Smith, BA Teply, MH Muders, SK Batra, K Datta, S Dutta
    Oncogene, 2022-07-19;40(3):111097.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  7. Coordinating Effect of VEGFC and Oleic Acid Participates to Tumor Lymphangiogenesis
    Authors: F Morfoisse, F De Toni, J Nigri, M Hosseini, A Zamora, F Tatin, F Pujol, JE Sarry, D Langin, E Lacazette, AC Prats, R Tomasini, J Galitzky, A Bouloumié, B Garmy-Susi
    Cancers, 2021-06-08;13(12):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  8. S1PR1 regulates the quiescence of lymphatic vessels by inhibiting laminar shear stress-dependent VEGF-C signaling
    Authors: X Geng, K Yanagida, RG Akwii, D Choi, L Chen, Y Ho, B Cha, MR Mahamud, K Berman de, H Ichise, H Chen, J Wythe, CM Mikelis, T Hla, RS Srinivasan
    JCI Insight, 2020-07-23;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  9. 6'-Sialylgalactose inhibits vascular endothelial growth factor receptor 2-mediated angiogenesis
    Authors: TW Chung, EY Kim, HJ Choi, CW Han, SB Jang, KJ Kim, L Jin, YJ Koh, KT Ha
    Exp. Mol. Med., 2019-10-11;51(10):120.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  10. Growth factor signaling regulates mechanical nociception in flies and vertebrates
    Authors: R Lopez-Bell, S Puig, PJ Huang, CR Tsai, HN Turner, MJ Galko, HB Gutstein
    J. Neurosci., 2019-05-28;0(0):.
    Species: Rat
    Sample Types: In Vivo
    Applications: Bioassay, In Vivo
  11. Matrix stiffness controls lymphatic vessel formation through regulation of a GATA2-dependent transcriptional program
    Authors: M Frye, A Taddei, C Dierkes, I Martinez-C, M Fielden, H Ortsäter, J Kazenwadel, DP Calado, P Ostergaard, M Salminen, L He, NL Harvey, F Kiefer, T Mäkinen
    Nat Commun, 2018-04-17;9(1):1511.
    Species: Human, Mouse
    Sample Types: Whole Cells
    Applications: Bioassay
  12. Arf6 in lymphatic endothelial cells regulates lymphangiogenesis by controlling directional cell migration
    Authors: YC Lin, N Ohbayashi, T Hongu, N Katagiri, Y Funakoshi, H Lee, Y Kanaho
    Sci Rep, 2017-09-12;7(1):11431.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  13. Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications
    Authors: KT Campbell, DJ Hadley, DL Kukis, EA Silva
    PLoS ONE, 2017-07-19;12(7):e0181484.
  14. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway
    Authors: S Yu, H Lv, H Zhang, Y Jiang, Y Hong, R Xia, Q Zhang, W Ju, L Jiang, G Ou, J Zhang, S Wang, J Zhang
    Biochem. Biophys. Res. Commun, 2017-02-13;0(0):.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human VEGF-C Protein

There are currently no reviews for this product. Be the first to review Recombinant Human VEGF-C Protein and earn rewards!

Have you used Recombinant Human VEGF-C Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review